December 2013 Issue of MMM
December 2013 Issue
What if pharmaceutical marketing could start again with a clean slate, reinvent age-old marketing instincts and put in place some things that we think would ...
Click the above link to access the complete Digital Edition of the December 2013 issue, with all text, charts and pictures.
Change is a drag, but there are still several positive signs to be seen in the landscape surrounding the evolving healthcare system, finds Larry Dobrow, ...
Sanford Bernstein's Dr. Tim Anderson and ISI Group's Dr. Mark Schoenebaum talk about the industry's prospects for 2014
These 16 agents, hand-picked from a total field of 164, are poised for approval, and possibly much more. Marc Iskowitz reports
Besides forcing industry to amass a torrent of new data, the Sunshine Act is also expected to wreak havoc on pharma-physician relations. Joe Dysart on ...
Pharma marketing is not without its flaws. Last month, seven seasoned industry execs discussed what they might change if they had a clean slate. James ...
Anna Protopapas, President, Millennium: The Takeda Oncology Co.
In 2014, the "new healthcare marketing" will become more discontinuous from the old
A new vaccine from Novartis, Bexsero, is a safe and effective tool against the strain of bacterial meningitis that caused a recent outbreak at Princeton.
Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial ...
News on Eisai, Vivus and Amarin
Med Ed Report
The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.
A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
The AHA/ACC panel that wrote the potentially practice-changing cholesterol guidelines issued last month included six members with ties to drugmakers that sell or are developing ...
News on Bayer Healthcare, Onyx Pharmaceuticals, Lilly, J&J, CMS and Community Care Behavioral Health Organization
The American Medical Association (AMA), together with a slew of co-signers, wants CMS to reverse a decision to include textbooks and journal reprints as reportable ...
The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.
News on Modern Healthcare, Journal of Lawand Biosciences and Neuro-Oncology
How are analytics, targeting and other forces augmenting ROI measurement?
Smartphone users, while in the exam room, are more apt to be in "switch mentality," a study finds.
Researchers found that most healthcare apps have limited functionality, don't serve patients with multiple needs, and taper off when support is needed most. No wonder ...
News from Pfizer, the National Institute on Drug Abuse, HealthTap and LEO Pharma
Eli Lilly promised a further easing in commercial outlays as it draws down sales force activity and advertising spend for two blockbusters whose patent expiries ...
Drugmakers looking for wiggle room should keep such hopes far from any drugs with a boxed warning.
Shionogi hopes the word "SEX" will attract women to Osphena via a beautiful two-page spread ad that recently ran in People and selected women's magazines.
When an FDA advisory panel met last month to vote on whether to recommend approval of Sanofi's MS drug Lemtrada, patient opinion leaders had already ...
The Centers for Medicare and Medicaid Services (CMS) unveiled a new research tool last month.
Saatchi & Saatchi Health Communications and Wellness merge, Heartbeat brought into the fold.
Mike Myers, president, and two other senior execs have left the agency Palio+Ignite, and a trio of long-time Palio leaders has assumed leadership of the ...
News on Clearpath Health Communications, Publicis,Omnicom, Incubate and Lilly
Keeping up with quality programs often feels like a safari in a jungle of government paperwork
Under pressure from Public Citizen and FDA, Dermatologic and Ophthalmic Drugs Advisory Committee chair Lynn Drake withdrew her acceptance of an invitation to provide a ...
Two researchers say that expedited review of new drugs may have exposed some patients to safety risks that had not been well characterized.
Brands that put the user first when building digital assets experienced a 50% drop in user errors
As customers use Triple Aim to drive healthcare quality, pharma will need to develop integrated offerings
These days, hitting the target in ads is ever more critical. These five ads are up to the challenge.
Shannyn Smith, EVP, managing director, Centron
At Work With
Sam Welch, Global Group President, Publicis Healthcare Communications Group
Promotions and hires for manufacturers, agencies and consultancies
As healthcare marketers and their agencies develop ever more digital customer solutions like mobile medical apps, it may be time to take a fresh look ...
Skill Sets (advertising section)
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.